UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D)
OF THE SECURITIES EXCHANGE ACT OF 1934
January 10, 2006
----------------
Date of Report (Date of earliest event reported)
ELITE PHARMACEUTICALS, INC.
---------------------------
(Exact name of registrant as specified in its charter)
Delaware 333-45241 22-3542636
-------- --------- ----------
(State or other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification No.)
165 Ludlow Avenue, Northvale, New Jersey 07647
----------------------------------------------
(Address of principal executive offices)
(201) 750-2646
--------------
(Registrant's telephone number, including area code)
--------------------------------------------------------------------------------
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
Act (17 CFR 240.13e-4(c))
Item 1.01. ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT.
On January 10, 2006, the Registrant and Elite Laboratories, Inc.,
its wholly owned subsidiary, entered into a Product Development and
Commercialization Agreement with Orit Laboratories LLC ("Orit"). The agreement
provides that Elite and Orit will co-develop and commercialize an extended
release drug product for treatment of anxiety, and, upon completion of
development, may license it for manufacture and sale. The parties intend to
develop all dose strengths of the product. The Registrant is to share in the
profits, if any from the sales of the drug. The term of the agreement is for the
longer of (i) a fifteen (15) year period from the date the product is first
commercially sold to a third party, or (ii) the life of applicable patent(s), if
any, whichever is longer. The agreement is automatically renewable for 3-year
periods unless terminated by either party by providing the other party with
twelve (12) months written notice prior to any renewal period.
Item 9.01. FINANCIAL STATEMENTS AND EXHIBITS
a) Not applicable.
b) Not applicable.
c) Exhibits
10.1 Product Development and Commercialization Agreement, dated
as of January 10, 2006, by and among Orit Laboratories LLC,
Elite Laboratories, Inc. and Elite Pharmaceuticals, Inc.*
99.1 Copy of Press Release, dated January 12, 2006
* The Registrant has requested confidential treatment with respect to the
referenced exhibit. In the event that the Securities and Exchange Commission
should deny such request in whole or in part, such exhibit or the relevant
portions thereof shall be filed by amendment to this Current Report on Form 8-K.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Dated: January 13, 2006
ELITE PHARMACEUTICALS, INC.
By: /s/ Bernard Berk
-----------------------------
Name: Bernard Berk
Title: Chief Executive Office